Director/PDMR Shareholding

RNS Number : 9855K

Hutchison China Meditech Limited

22 April 2015

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Director's Shareholding

London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP18.00 per share on 21 April 2015.

Following this purchase, Mr Nash is beneficially interested in 31,930 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:	[phone]
Panmure Gordon (UK) Limited Richard Gray Andrew Potts	Telephone:	[phone]
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone: Mobile: Mobile:	[phone] [phone] [phone]

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

 

END

 

 

RDSBGGDSBDDBGUD